Avadel Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
Avadel Pharmaceuticals plc (Nasdaq: AVDL) has announced that its management will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 15, 2023, at 1:00 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Avadel Pharmaceuticals plc (Nasdaq: AVDL) has announced that its management will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 15, 2023, at 1:00 p.m. ET. A live webcast and archived recording of the chat will be accessible on Avadel’s Investor Relations website for 90 days post-conference. Avadel is focused on innovative biopharmaceutical solutions, particularly an investigational sodium oxybate formulation aimed at treating cataplexy and excessive daytime sleepiness in adults with narcolepsy. For further details, visit www.avadel.com.
Details
News Market Reaction – AVDL
The recorded move for AVDL in the trading session of this news was +0.26%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DUBLIN, Ireland, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15 at 1:00 p.m. ET.
A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following the conference.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:
Courtney Turiano
Stern Investor Relations, Inc.
Courtney.Turiano@sternir.com
(212) 698-8687
Media Contact:
Gabriella Greig
Real Chemistry
ggreig@realchemistry.com
(203) 249-2688
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.